> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# First-line SGLT2 inhibitors versus metformin and cardiorenal outcomes in type 2 diabetes
- URL: https://www.coios.me/first-line-sglt2-inhibitors-versus-metformin-and/
- Published: 2026-11-19T13:05:35.000Z
- Updated: 2026-11-19T16:01:38.000Z
- Description: In 36,720 matched pairs, starting SGLT2 inhibitors over metformin was associated with lower risk of major cardiovascular events and death.
- Author: Daniel Ryan
- Tags: Health today, Obesity, diabetes and GLP-1, Innovation in treatment, World, #peer-reviewed, #refines, #item, #source-2026-11, #score-65

This target trial emulation compared adults with type 2 diabetes starting SGLT2 inhibitors or metformin as first-line therapy. Records from a global research network gave 36,720 propensity-matched pairs of new users, 2018 to 2023\. SGLT2 inhibitor initiation was associated with lower risk of major adverse cardiovascular events (HR 0.88) and all-cause mortality (HR 0.73). Risks of stroke (HR 0.84), cardiac arrest (HR 0.81) and acute heart failure (HR 0.94) were also lower. Myocardial infarction (HR 0.97) and kidney failure needing replacement therapy (HR 1.00) did not differ. The design is observational, and median follow-up was shorter for SGLT2 inhibitors (2.5 years) than for metformin (3.5 years).

*Why it is interesting: The study compares two first-line drugs in type 2 diabetes head to head. SGLT2 inhibitors were linked to fewer deaths, but not to fewer heart attacks or kidney failures.*

Source

[Mayo Clinic Proceedings, 18 November 2026](https://doi.org/10.1016/j.mayocp.2026.10.024?ref=coios.me)

Paper

SGLT2 Inhibitors Versus Metformin as First-Line Therapy for Cardiorenal Outcomes: A Target Trial Emulation Among New Users With Type 2 Diabetes

Authors

Kung FP, Tsai CF, Chang YT

DOI

10.1016/j.mayocp.2026.10.024

Type

Peer-reviewed article

Design

Target trial emulation in TriNetX global EHR network, new users 2018-2023 followed to June 2025, 36,720 propensity-matched pairs

Verdict

Refines prior evidence

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)

Driver

[Innovation in treatment](https://www.coios.me/d-treatment-innovation/)